This phase 2 trial tests whether the supplement fisetin can improve lung disease in people with common variable immunodeficiency (CVID). Twenty participants will receive either fisetin or a placebo on four days over a month. The study measures changes in immune cells and lung fun…
Phase: PHASE2 • Sponsor: Avni Joshi • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC